(Hong Kong, 6 November 2009) - Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharmaceutical” or the “Group”, Stock Code: 8221), announced that it has successfully completed the dosing of the first two subjects in its Phase IA clinical trial in which Declotana® is being tested in 20 healthy subjects.